Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the International Global RESOLUTE Program

JACC: Cardiovascular Interventions

Volumn 6, Issue 4, 2013, Pages 357-368

  Silber, Sigmund ^a   Serruys, Patrick W ^b   Leon, Martin B ^c   Meredith, Ian T ^d   Windecker, Stephan ^e   Neumann, Franz Josef ^f   Belardi, Jorge ^g   Widimsky, Petr ^h   Massaro, Joe ⁱ   Novack, Victor ^j   Yeung, Alan C ^k   Saito, Shigeru ^l   Mauri, Laura ^m  

^a Heart Center at the Isar   (Germany)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Department of Medicine   (United States)

^d MONASH UNIVERSITY   (Australia)

^e University Hospital Foundation   (Switzerland)

^f UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^g INSTITUTO CARDIOVASCULAR DE BUENOS AIRES   (Argentina)

^h CHARLES UNIVERSITY   (Czech Republic)

ⁱ HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^j Soroka Clinical Research Center   (Israel)

^k STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l SHONAN KAMAKURA GENERAL HOSPITAL   (Japan)

^m BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

clinical outcome; diabetes mellitus; percutaneous coronary intervention (PCI); zotarolimus eluting stent

Indexed keywords

EVEROLIMUS; ZOTAROLIMUS;

ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY BYPASS SURGERY; DIABETES MELLITUS; DRUG ELUTING STENT; HEART DEATH; HEART DISEASE; HUMAN; INCIDENCE; INSULIN TREATMENT; MAJOR CLINICAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; STENT THROMBOSIS; TREATMENT OUTCOME;

AGED; CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DEVICE APPROVAL; DIABETES MELLITUS; DRUG-ELUTING STENTS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RISK FACTORS; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84876417156     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2012.11.006     Document Type: Article

References (47)

1. S.M. Grundy, R.B. D'Agostino Sr, L. Mosca Cardiovascular risk assessment based on US cohort studies: findings from a National Heart, Lung, and Blood Institute workshop Circulation 104 2001 491 496
2. T.K. Schramm, G.H. Gislason, L. Køber Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people Circulation 117 2008 1945 1954
3. L. Rydén, E. Standl, M. Bartnik Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur Heart J 28 2007 88 136
4. K.E. Kip, D.P. Faxon, K.M. Detre, W. Yeh, S.F. Kelsey, J.W. Currier Coronary angioplasty in diabetic patients The National Heart, Lung, and Blood Institute percutaneous transluminal coronary angioplasty registry Circulation 94 1996 1818 1825
5. R. Kornowski, G.S. Mintz, K.M. Kent Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia A serial intravascular ultrasound study Circulation 95 1997 1366 1369
6. I. Iakovou, T. Schmidt, E. Bonizzoni Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents JAMA 293 2005 2126 2130
7. M. Sabaté, P. Jiménez-Quevedo, D.J. Angiolillo Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial Circulation 112 2005 2175 2183
8. D. Baumgart, V. Klauss, F. Baer One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients J Am Coll Cardiol 50 2007 1627 1634
9. A. Maresta, E. Varani, M. Balducelli Comparison of effectiveness and safety of sirolimus-eluting stents versus bare-metal stents in patients with diabetes mellitus (from the Italian multicenter randomized DESSERT study) Am J Cardiol 101 2008 1560 1566
10. W.J. Kim, S.W. Lee, S.W. Park Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial Circ Cardiovasc Interv 124 2011 886 892
11. S.R. Mulukutla, H.A. Vlachos, O.C. Marroquin Impact of drug-eluting stents among insulin-treated diabetic patients: a report from the National Heart, Lung, and Blood Institute dynamic registry J Am Coll Cardiol Intv 1 2008 139 147
12. S. Minha, T. Bental, A. Assali A comparative analysis of major clinical outcomes using drug-eluting stents versus bare metal stents in diabetic versus nondiabetic patients Catheter Cardiovasc Interv 78 2011 710 717
13. A. Abizaid, M.A. Costa, D. Blanchard Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients Insights from the RAVEL trial Eur Heart J 25 2004 107 112
14. I. Moussa, M.B. Leon, D.S. Baim Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy Circ Cardiovasc Interv 109 2004 2273 2278
15. J.B. Hermiller, A. Raizner, L. Cannon Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial J Am Coll Cardiol 45 2005 1172 1179
16. S.J. Hong, M.H. Kim, T.H. Ahn Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes Heart 92 2006 1119 1124
17. R. Kumar, T.T. Lee, A. Jeremias Comparison of outcomes using sirolimus-eluting stenting in diabetic versus nondiabetic patients with comparison of insulin versus non-insulin therapy in the diabetic patients Am J Cardiol 100 2007 1187 1191
18. T. Bauer, H. Möllmann, F. Weidinger Impact of diabetes mellitus status on coronary pathoanatomy and interventional treatment: insights from the Euro Heart Survey PCI Registry Catheter Cardiovasc Interv 78 2011 702 709
19. K. Udipi, M. Chen, P. Cheng Development of a novel biocompatible polymer system for extended drug release in a next-generation drug-eluting stent J Biomed Mater Res A 85A 2008 1064 1071
20. I.T. Meredith, S. Worthley, R. Whitbourn Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial J Am Coll Cardiol Intv 2 2009 977 985
21. P.W. Serruys, S. Silber, S. Garg Comparison of zotarolimus-eluting and everolimus-eluting coronary stents N Engl J Med 363 2010 136 146
22. S. Silber, S. Windecker, P. Vranckx, P.W. Serruys RESOLUTE All Comers Investigators Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE all comers trial Lancet 377 2011 1241 1247
23. A.C. Yeung, M.B. Leon, A. Jain Clinical evaluation of the resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial J Am Coll Cardiol 57 2011 1778 1783
24. F.J. Neumann, P. Widimsky, J.A. Belardi One-year outcomes of patients with the zotarolimus-eluting coronary stent: RESOLUTE International registry EuroIntervention 7 2012 1181 1188
25. Saito S. RESOLUTE Japan 12 month results. Presented at the 20th Annual Meeting of the Japanese Association of Cardiovascular Intervention and Therapeutics in Osaka: Japan, 2011.
26. L. Mauri, J.M. Massaro, S. Jiang Long-term clinical outcomes with zotarolimus-eluting versus bare-metal coronary stents J Am Coll Cardiol Intv 3 2010 1240 1249
27. L. Mauri, M.B. Leon, A.C. Yeung, M. Negoita, M.J. Keyes, J.M. Massaro Rationale and design of the clinical evaluation of the resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries (the RESOLUTE US clinical trial) Am Heart J 161 2011 807 814
28. D.E. Cutlip, S. Windecker, R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
29. I. Moussa, M.B. Leon, D.S. Baim Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy Circulation 109 2004 2273 2278
30. L. Mauri, J.M. Massaro, S. Jiang Long-term clinical outcomes with zotarolimus-eluting versus bare-metal coronary stents J Am Coll Cardiol 3 2010 1240 1249
31. M.A. Turco, J.A. Ormiston, J.J. Popma Polymer-based, paclitaxel-eluting TAXUS liberte stent in de novo lesions: the pivotal TAXUS ATLAS trial J Am Coll Cardiol 49 2007 1676 1683
32. I.T. Meredith, R. Whitbourn, D. Scott Platinum QCA: a prospective, multicentre study assessing clinical, angiographic, and intravascular ultrasound outcomes with the novel platinum chromium thin-strut PROMUS Element everolimus-eluting stent in de novo coronary stenoses EuroIntervention 7 2011 84 90
33. K.G. Alberti, P.Z. Zimmet Definition, diagnosis and classification of diabetes mellitus and its complications Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation Diabet Med 15 1998 539 553
34. S. Silber, P. Albertsson, F.F. Avilés Guidelines for percutaneous coronary interventions: the Task Force for percutaneous coronary interventions of the European Society of Cardiology Eur Heart J 26 2005 804 847
35. W. Wijns, P. Kolh, N. Danchin Guidelines on myocardial revascularization Eur Heart J 31 2010 2501 2555
36. G.N. Levine, E.R. Bates, J.C. Blankenship ACCF/AHA/SCAI guideline for percutaneous coronary intervention A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions J Am Coll Cardiol 58 2011 e44 e122
37. A. Dibra, A. Kastrati, J. Mehilli Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients N Engl J Med 353 2005 663 670
38. S.W. Lee, S.W. Park, Y.H. Kim A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus 2-year clinical outcomes of the DES-DIABETES trial J Am Coll Cardiol 53 2009 812 813
39. F. Zhang, L. Dong, J. Ge Meta-analysis of five randomized clinical trials comparing sirolimus- versus paclitaxel-eluting stents in patients with diabetes mellitus Am J Cardiol 105 2010 64 68
40. C. Patterson, S. Mapera, H.H. Li Comparative effects of paclitaxel and rapamycin on smooth muscle migration and survival: role of AKT-dependent signaling Arterioscler Thromb Vasc Biol 26 2006 1473 1480
41. G.W. Stone, E. Kedhi, D.J. Kereiakes Differential clinical responses to everolimus-eluting and paclitaxel-eluting coronary stents in patients with and without diabetes mellitus Circulation 124 2011 893 900
42. A. Abizaid, R. Kornowski, G.S. Mintz The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation J Am Coll Cardiol 32 1998 584 589
43. T.H. Yang, S.W. Park, M.K. Hong Impact of diabetes mellitus on angiographic and clinical outcomes in the drug-eluting stents era Am J Cardiol 96 2005 1389 1392
44. J. Fajadet, W. Wijns, G.J. Laarman Randomized, double-blind, multicenter study of the endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial Circ Cardiovasc Interv 114 2006 798 806
45. D.E. Kandzari, M.B. Leon, J.J. Popma Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial J Am Coll Cardiol 48 2006 2440 2447
46. M.B. Leon, L. Mauri, J.J. Popma A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial J Am Coll Cardiol 55 2010 543 554
47. M.E. Farkouh, M. Domanski, L.A. Sleeper FREEDOM Trial Investigators Strategies for multivessel revascularization in patients with diabetes N Engl J Med 367 2012 2375 2384